Company Spotlight features video, webcasts, presentations and annual reports for more than 30,000 companies. Sign up to promote your company. ×

Commercial Physical And Biological Research NY, United States
Nasdaq: KERX
Keryx Biopharmaceuticals, Inc. is a biopharmaceutical company. It acquires, develops, and commercializes medically important pharmaceutical products for the treatment of cancer and renal disease. It develops KRX-0401 (perifosine), a novel, potentially first-in-class, oral anti-cancer agent that inhibits Akt activation in the phosphoinositide 3-kinase, or PI3K, pathway, and also affects a number of other key signal transduction pathways, including the JNK pathway, all of which are pathways associated with programmed cell death, growth, differentiation and survival. The company also develops Zerenex (ferric citrate), an oral, ferric iron-based compound that has the capacity to bind to phosphate in the gastrointestinal tract and form non-absorbable complexes. Keryx Biopharmaceuticals was founded in October 1998 and is headquartered in New York, NY.
Similar to: Medivir AB, Exelixis, Inc., Advanced Cell Technology, Inc.
Hanley, ST, GB
Goodwin Plc provides machining, general engineering, valves and Pumps. The firm operates casting, melting, refining, assembly and… Learn more →

Marlborough, MA, US
Advanced Cell Technology, Inc. is a biotechnology company that develops cellular therapies for the treatment of rare and common diseases… Learn more →

South San Francisco, CA, US
Exelixis, Inc. develops human therapeutics by innovating therapies for cancer and other serious diseases to various pharmaceutical… Learn more →

Stockholm, SE
Medivir is a research based pharmaceutical company focused on infectious diseases and Nordic market presences were we market 15 products… Learn more →